Hypoxia-driven ncRNAs in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Hypoxia, or low oxygen tension, drives tumor aggressiveness, therapy resistance, metastasis, and stemness in breast cancer.
• The non-coding genome, including microRNAs, long non-coding RNAs, and circular RNAs, plays a crucial role in cancer progression.
• Hypoxia-responsive non-coding RNAs are increasingly implicated in the development and progression of breast cancer.

Purpose of the Study:

• To review the regulatory roles of hypoxia-responsive non-coding RNAs in breast cancer.
• To elucidate the molecular mechanisms by which these non-coding RNAs contribute to tumor aggressiveness.
• To explore the therapeutic potential of targeting hypoxia-driven non-coding RNAs in breast cancer.

Main Methods:

• Literature review of studies investigating hypoxia and non-coding RNAs in breast cancer.
• Analysis of molecular mechanisms linking hypoxia-inducible factors (HIFs) and non-coding RNA expression.
• Evaluation of current and potential clinical applications of hypoxia-driven non-coding RNAs.

Main Results:

• Hypoxia modulates the expression of various non-coding RNAs, acting as both upstream regulators and downstream effectors of HIF signaling.
• These non-coding RNAs orchestrate aggressive tumor microenvironments and regulate key cancer processes like proliferation, migration, invasion, and immune evasion.
• Interplay and feedback loops between non-coding RNAs and HIFs further drive breast cancer progression.

Conclusions:

• Hypoxia-driven non-coding RNAs are critical players in breast cancer aggressiveness and metastasis.
• While currently used for prognostics and diagnostics, these non-coding RNAs represent promising therapeutic targets for aggressive breast cancers.
• Targeting hypoxia-driven non-coding RNAs holds significant potential for future breast cancer treatment and reducing the global cancer burden.